What is the recommended treatment for nonspecific interstitial pneumonia (NSIP)?

Treatment of NSIP

For idiopathic nonspecific interstitial pneumonia (NSIP), initiate systemic corticosteroids as first-line therapy, with consideration for adding immunosuppressive agents (azathioprine or mycophenolate) for combination therapy, particularly in patients with more severe disease or those requiring prolonged treatment.

First-Line Treatment Approach

The standard treatment for idiopathic NSIP centers on immunosuppression, as the disease is thought to be an inflammatory-driven process 1, 2. While the evidence base is limited, corticosteroid-based therapy has demonstrated significant improvements in lung function:

• Corticosteroid monotherapy or combination therapy improves FVC by approximately 10%, FEV1 by 9.8%, and DLco by 8.4% after 1 year of treatment 3
• Treatment response is more pronounced when initiated early in the disease course 3

Combination Immunosuppression

For patients requiring prolonged therapy or with more severe disease, add azathioprine or mycophenolate to corticosteroids 4, 5. The combination of corticosteroids with azathioprine specifically has been associated with:

• Lower risk of disease progression or relapse (adjusted HR 0.556) 5
• Better long-term outcomes compared to corticosteroid monotherapy

Other immunosuppressive options include cyclophosphamide, cyclosporine, and mycophenolate mofetil, though these are less well-studied 4.

Factors Predicting Treatment Response

Initiate treatment early—shorter symptom duration at diagnosis predicts better treatment response 3. Key prognostic indicators include:

• Favorable factors: Negative ANA serology, shorter symptom duration, DLco ≥60%, BAL lymphocytosis >15% 3, 5
• Poor prognostic factors: Positive ANA (associated with non-response), DLco <60%, absence of BAL lymphocytosis 3, 5

Patients with positive ANA may have underlying connective tissue disease and should be evaluated accordingly, as this changes the diagnostic category from idiopathic to secondary NSIP 3.

Critical Diagnostic Caveat

Before treating as idiopathic NSIP, rigorously exclude secondary causes—particularly connective tissue diseases, drug toxicity, and environmental exposures 2, 6. A thorough exposure history and autoimmune workup are essential, as positive findings would indicate secondary NSIP requiring different management considerations 6.

Progressive Pulmonary Fibrosis

For patients who develop progressive pulmonary fibrosis (PPF) despite immunosuppression, consider antifibrotic agents (nintedanib or pirfenidone) 2. This represents a distinct clinical scenario where the disease behaves more like a progressive fibrosing phenotype despite the NSIP pattern.

Monitoring and Long-Term Management

• Monitor lung function (FVC, DLco) at regular intervals to assess treatment response
• Disease progression or relapse occurs in approximately 49% of patients and is a significant risk factor for mortality (adjusted HR 7.135) 5
• The 5-year survival rate exceeds 70% in most studies, significantly better than idiopathic pulmonary fibrosis 2, 4

Treatment Algorithm Summary

1. Confirm idiopathic NSIP through multidisciplinary discussion and exclusion of secondary causes
2. Initiate corticosteroids as first-line therapy
3. Add azathioprine or mycophenolate for severe disease, prolonged therapy needs, or suboptimal response
4. Monitor closely for treatment response and disease progression
5. Consider antifibrotics if progressive pulmonary fibrosis develops despite immunosuppression
6. Refer for lung transplantation in cases of severe, refractory disease

The prognosis remains favorable compared to IPF, but the disease carries attributable mortality and requires vigilant monitoring for progression 6, 5.